

**CURICULUM VITAE**

**ATHANASIOS KOTSAKIS, M.D., PhD**

**ASSISTANT PROFESSOR OF MEDICAL ONCOLOGY  
SCHOOL OF MEDICINE, UNIVERSITY OF CRETE  
HERAKLION, CRETE, GREECE**

**July 2014**

## PERSONAL INFORMATION:

**Name** Athanasios Kotsakis  
**Date of birth:** 17.9.1968, Athens, Greece  
**Citizenship:** Greek  
**Marital status:** Married with 3 children  
**Address:** University Hospital of Heraklion, Department of Medical Oncology, Stavrakia and Voutes, PO Box 1352, Heraklion, 71110, Crete, Greece.  
**Telephone No:** +30 6944 865901, +30 2810 392 783  
**Telefax No:** +30 2810 543 601  
**e-mail:** [thankotsakis@hotmail.com](mailto:thankotsakis@hotmail.com), [kotsakis@med.uoc.gr](mailto:kotsakis@med.uoc.gr)

## EDUCATION:

24.04.1996 Degree in Medicine (National and Capodistrian University of Athens)  
12.01.2006 Specialty in Medical Oncology  
02.07.2008 Ph.D Thesis (School of Medicine, University of Crete).  
Title of thesis: "Prospective study of the impact of the anticancer drugs on T-cell lymphocytes"  
15-19/2/2012 ICH- GCP Training (Certificate of Completion Investigator)

## FOREIGN LANGUAGES

English

## MEMBERSHIP OF SOCIETIES

- 1 General Medical Council (UK)
- 2 ASCO (American Society of Clinical Oncology)
- 3 ETOP (European Thoracic Oncology Platform)
- 4 EORTC (European Organization for Research and Treatment of Cancer)
- 5 HeSMO (Hellenic Society of Medical Oncology)
- 6 HORG (Hellenic Oncology Research Group)

## EDUCATION AND TRAINING

07.1996	Medical License, (Resolution 14202-Prefecture of Athens, Greece).
02.2004	Medical License, (Resolution. GENERAL MEDICAL COUNCIL; GMC) (U.K).
08.1996- 09.1997	General Practitioner (rural service)
09.1996- 09.1997	Department of Medical Oncology, University Hospital of Heraklion, Greece. (Detachment from Rural Health Centre)
09.1997- 04.1999	Military Service (Air Force Doctor).
05.1999- 09.1999	Research Assistant (Dept. of Medical Oncology, University General Hospital of Heraklion, Greece).
09.1999- 09.2001	Training in Internal Medicine (Intern; Dept. of Therapeutics, University Hospital "ALEXANDRA", Athens, Greece).
09.2001- 11.2001& 05.2002- 11.2002	Research Assistant (Dept. of Medical Oncology, University General Hospital of Heraklion, Greece).
11.2001- 05.2002	Training in Hematology (Intern; 3 <sup>rd</sup> Dept. of Internal Medicine, University Hospital "Sotiria", Athens, Greece).
11.2002- 11.2005	Training in Oncology (Intern; Dept. of Medical Oncology, University General Hospital of Heraklion, Greece).
(02.2004- 08.2004)	Training in Medical Oncology (Dept. of Medical Oncology, Guy's Hospital, London, UK (Consultant. P. Harper).
01.2006 – 05.2007	Clinical researcher, (Dept. of Medical Oncology, University Hospital of Heraklion, Greece).
05.2007- 01.2012	Attending Medical Oncologist (Dept. of Medical Oncology, University Hospital of Heraklion, Greece).
01.2012- 04.2014	Lecturer of Medical Oncology (School of Medicine, University of Crete)
04.2014- present	Assistant Professor of Medical Oncology (School of Medicine, University of Crete)

## POST SPECIALIZATION TRAINING

- 11-17. 2. 2006 Masterclass in Clinical Oncology, (European School of Oncology)
- 09.2008- 08.2011 Research Fellow, University of Pittsburgh Medical Center (UPMC), Department of Medical Oncology, Pittsburgh, Pennsylvania, USA
- 06.2009- 08.2011 Research Fellow, UPMC, Department of Immune Monitoring and Cellular Processing Laboratory (IMCPL), Pittsburgh, Pennsylvania, USA

## HONORS

2008: Scholarship (Hellenic Society of Medical Oncology) for post specialization training in the University of Pittsburgh Medical Center, Department of Medical Oncology, Pittsburgh, Pennsylvania, USA.

2010: Scholarship (Hellenic Society of Medical Oncology) for post specialization training in the University of Pittsburgh, Department of Immune Monitoring and Cellular Processing Laboratory (IMCPL), Pittsburgh, Pennsylvania, USA.

2011: 1st award for the work entitled "Clinical and immunologic response of patients with advanced Non-Small Cell Lung Cancer (NSCLC) vaccinated with an optimized cryptic hTERT peptide (Vx-001)", **Kotsakis A.**, Vetsika E.K., Agouraki D, et al., Advances and Perspectives in Thoracic and upper Aerodigestive Malignancies 10-13 March 2011, Athens, Greece.

2011: 1st award (Hellenic Society of Medical Oncology) for the work entitled "A phase II study of bortezomib in combination with doxorubicin in recurrent or metastatic adenoid cystic carcinoma of the head and neck", **Kotsakis A.**, Argiris A. Forum of Clinical Oncology (issue 2, vol 2, June 2011).

## EDUCATIONAL ACTIVITY

2005- 2008 & Training of medical students at the University of Crete in Internal Medicine  
2011- present

2006 -2008 & Attendance in the clinical and theoretical Training of medical oncology fellows in  
2011- present the University General Hospital, Department of Medical Oncology

2006- present Participation, as speaker, in seminars in the department of Medical Oncology of University of Crete (Summer Schools, Postgraduate Conferences in Medical Oncology) focusing on immunology/ cancer immunotherapy and issues having a relationship with new biological agents in the treatment of cancer.

## RESEARCH

### I. CLINICAL RESEARCH

2006-2008 Co-investigator in the clinical trial entitled “ Phase I Study:Immunotherapy of Chemoresistant Cancer in patients with TERT- derived optimized cryptic peptide”

09/2008-08/2011 Clinical Research (design, monitoring and analysis) in University of Pittsburgh Medical Center- Pennsylvania, USA

#### ***Clinical trials***

- A phase II study of bortezomib in combination with doxorubicin in recurrent or metastatic adenoid cystic carcinoma of the head and neck
- Phase II study of everolimus (RAD001) in previously treated small cell lung cancer (SCLC)
- Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN)
- A Phase I Study of ABT-888 in Combination with carboplatin and paclitaxel in advanced solid malignancies
- A Phase II Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
- A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus

High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

- Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).
- A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

2006-2008 & Organization, management and supervision of the International Clinical Research  
09/2011- present Program of the Department of Medical Oncology, University General Hospital of Heraklion, Crete

## CLINICAL TRIALS EXPERIENCE

### A) INTERNATIONAL CLINICAL STUDIES

#### As Principal- Investigator

<b>Study</b>
Epidemiology and treatment of metastatic breast cancer in Greece: A retrospective cohort study- "EMERGE" trial

#### As Sub-Investigator

<b>Tumor</b>	<b>Total of studies</b>
Breast Cancer	19
Lung Cancer	25
Colorectal Cancer	7
Head Neck Cancer	2
Renal cell carcinoma	3
Prostate Cancer	7
Ovarian Cancer	4
Other Neoplasms	15
Total:	100

### B) INVESTIGATOR SPONSORED TRIALS

#### As Principal- Investigator

<b>Study</b>
CT 12.02 A pilot phase II of Cabazitaxel in patients with metastatic non-small cell lung cancer progressing after Docetaxel-based treatment

#### As Sub-Investigator

<b>Tumor</b>	<b>Total of studies</b>
Breast Cancer	2
Lung Cancer	2
Colorectal Cancer	2
Prostate Cancer	1
Stomach Cancer	2
Other Neoplasms	1
Total:	10

## II. TRANSLATIONAL RESEARCH

- 09/2009-8/2011 Investigation of immune suppressive mechanisms in cancer patients.  
Department of Immune Monitoring and Cellular Processing Laboratory (IMCPL)- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Trial as Principal Investigator***
- Prospective study of the effects of chemoradiotherapy on regulatory T-cells (Treg) in patients with locally advanced squamous cell carcinoma of the head and neck
- 09/2011- present Supervisor of the Immunology Group; Laboratory of Tumor cell Biology, School of Medicine, University of Crete.

## ORGINIZING EXPERIENCE

- 09/2011- present Organization, management and supervision of the International Clinical  
09/2006- 09/2008 Research Program of the Department of Medical Oncology, University General Hospital of Heraklion, Crete
- 2012 & 2013 Organization and scientific supervision of the 5<sup>th</sup> and 6<sup>th</sup> "Summer Schools" in Medical Oncology
- 09/2006- 09/2008 Coordination and monitoring of the clinical part of the research program of study entitled "Phase I study: Immunotherapy of chemoresistant cancer patients with TERT-derived optimized cryptic peptide"



## PUBLICATIONS

### A) Chapters in Textbooks

1. **Athanasios Kotsakis**, Michael K. Gibson and Athanassios Argiris: Incorporating Novel Agents with Chemotherapy and Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Multidisciplinary Management of Head and Neck Cancer. R. Haddad, Chapter 6, p 99-142, 2010.
2. Athanassios Argiris and **Athanasios Kotsakis**: Update on Targeted Therapies for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ASCO Educational Book Manuscript, p 218-223, 2011.
3. **A. Kotsakis**, E. Kontopodis, and V. Georgoulas: Pros and Cons of Maintenance Therapy for Advanced Non- Small Cell Lung Cancer. Emerging Cancer Therapeutics, 3:1, 27-44, 2012
4. **A Kotsakis**, N Kentepozidis and V Georgoulas. Metronomic Chemotherapy in Non-Small-Cell Lung Cancer. Metronomic Chemotherapy, 2014 (in press)

### B) In International Journals

1. V. Georgoulas, Ch. Kouroussis, S. Kakolyris, N. Androulakis, MA. Dimopoulos, E. Papadakis, **Th. Kotsakis**, N. Vardakis, K. Kalbakis, N. Merambeliotakis, D. Hatzidaki: Second-line treatment of advanced non-small cell lung cancer with Paclitaxel and Gemcitabine: A preliminary report on an active regimen. Semin Oncol 24(suppl 12): 61, 1997.
2. V. Georgoulas, Ch. Kouroussis, N. Androulakis, S. Kakolyris, M-A. Dimopoulos, Ch. Papadimitriou, K. Hatzakis, P. Heras, K. Kalbakis, **Th. Kotsakis**, N. Vardakis, N. Merambeliotakis, D. Hatzidaki: Docetaxel (Taxotere) and Gemcitabine (Gemsar) in the treatment of non-small cell lung cancer (NSCLC): Preliminary results. Semin Oncol 24 (suppl 14): 22-25, 1997.
3. S. Kakolyris, N. Androulakis, Ch. Kouroussis, **A. Kotsakis**, J. Souglakos, D. Hatzidaki, D. Beri, G. Samonis, V. Georgoulas: Vinorelbine and tamoxifen as first-and second-line treatment in elderly patients with advanced breast cancer: A preliminary analysis. J BUON 3: 219-226, 1997.
4. M.I. Koukourakis, C. Kouroussis, M. Kamilakis, S. Koukouraki, A. Giatromanolaki, S. Kakolyris, **A. Kotsakis**, N. Androulakis, N. Bachlitzanakis, V. Georgoulas: Weekly

docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer: A phase I/II dose escalation trial. *Eur J Cancer* 34 (6): 838-844, 1998.

5. V. Georgoulis, N. Androulakis, D. Bouros, Ch. Kouroussis, K. Chatzakis, E. Papadakis, F. Apostolopoulou, Th. Georgopoulou, **T. Kotsakis**, J. Souglakos, D. Hatzidaki, J. Vlachonikolis, G. Panagos: Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small cell lung cancer: A multicenter phase II study of the Greek Cooperative Group for Lung Cancer. *Lung Cancer* 21: 213-220, 1998.
6. N. Androulakis, Ch. Kouroussis, S. Kakolyris, S. Tzannes, E. Papadakis, Ch. Papadimitriou, A. Geroyianni, Th. Georgopoulou., I. Dimopoulou, J. Souglakos, **A. Kotsakis**, N. Vardakis, D. Hadzidaki, V. Georgoulis: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin-or-docetaxel-based chemotherapy: A multicenter phase II study. *Ann Oncol* 9: 1127-1130, 1998.
7. Ch. Kouroussis, N. Androulakis, S. Kakolyris, J. Souglakos, **T. Kotsakis**, D. Mavroudis, K. Katsogridakis, N. Vardakis, D. Hatzidaki, G. Samonis, J. Vlachonikolis, V. Georgoulis: Dose-escalation study of docetaxel in combination with mitoxantrone as first line treatment in patients with metastatic breast cancer. *J Clin Oncol* 17 (3): 862-869, 1999.
8. V. Georgoulis, Ch. Kouroussis, N. Androulakis, S. Kakolyris, AM. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, Ch. Papadimitriou, A. Agelidou, K. Hatzakis, K. Kalbakis, **A. Kotsakis**, N. Vardakis, J. Vlachonikolis: Front line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. *J Clin Oncol* 17 (3): 914-920, 1999.
9. E. Sarra, **A. Kotsakis**, J. Souglakos, Ch. Kouroussis, S. Kakolyris, E. Mavromanolakis, J. Vlachonikolis, V. Georgoulis: Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4<sup>+</sup> cell proliferation. *Anticancer Res* 19: 471-476, 1999.
10. **A. Kotsakis**, E. Sarra, M. Peraki, M. Koukourakis, S. Apostolaki, J. Souglakos, E. Mavromanolakis, J. Vlachonikolis, V. Georgoulis: Docetaxel-induced lymphopenia in patients with solid tumors: A prospective phenotypic analysis. *Cancer* 15(89): 1380-1386, 2000.
11. Ch. Kouroussis, G. Samonis, N. Androulakis, J. Souglakos, A. Voloudaki, A.M. Dimopoulos, **T. Kotsakis**, S. Kakolyris, K. Kalbakis, V. Georgoulis: Successful conservative treatment of neutropenic enterocolitis complicating taxane based chemotherapy: a report of five cases. *Am J Clin Oncol* 23(3): 309-313, 2000.
12. S. Kakolyris, J. Souglakos, Ch. Kouroussis, N. Androulakis, D. Mavroudis, K. Kalbakis, **A. Kotsakis**, N. Vardakis, M. Koukourakis, J. Romanos, V. Georgoulis: A dose-finding study of irinotecan (CPT-11) plus 4-day continuous 5-fluorouracil (5-FU) infusion in advanced colorectal cancer. *Oncology* 60(3): 207-213, 2001.
13. A.Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, **A. Kotsakis**, N. Xenidis, D. Reppa, V.

Georgoulas: Molecular Detection of Cytokeratin-19 positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. *J Clin Oncol* 20 (16): 3404-3412, 2002.

14. Souglakos J, **Kotsakis A**, Kouroussis C, Kakolyris S, Mavroudis D, Kalbakis K, Agelaki S, Vlachonikolis J, Georgoulas V, Samonis G. Nonneutropenic febrile episodes associated with docetaxel based chemotherapy in patients with solid tumors. *Cancer*. 2002 Sep 15;95(6):1326-33.
15. J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, **A. Kotsakis**, V. Georgoulas: Combination of irinotecan (CPT-11) plus Oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicancer phase II trial. *Ann Oncol* 15: 1204-1209, 2004.
16. A. Pallis, A. Agelidou, P. Papakotoulas, A. Tsaroucha, M. Agelidou, S. Agelaki, N. Androulakis, L. Vamvakas, A. Geroyianni, **A. Kotsakis**, N. Kentepozidis, V. Georgoulas: A multicentre phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. *Lung Cancer* 52: 165-171, 2006.
17. A. Ardavanis, D. Mavroudis, K. Kalbakis, N. Malamos, K. Syrigos, L. Vamvakas, **A. Kotsakis**, N. Kentepozidis, Ch. Kouroussis, S. Agelaki, V. Georgoulas : Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: A multicentre phase II study. *Cancer Chem Pharm* 58: 742-748, 2006.
18. I. Boukovinas, N. Androulakis, L. Vamvakas, P. Papakotoulas, N. Ziras, A. Kalykaki, **A. Kotsakis**, I. Gioulmbasanis, D. Mavroudis, V. Georgoulas: Sequential gemcitabine and cisplatin followed by doxorubicin as first-line treatment of advanced urothelial carcinoma: a multicentre phase II study of the Hellenic Oncology research Group (HORG). *Ann Oncol* 17: 1687-692, 2006.
19. G.P. Stathopoulos, K. Syrigos, G. Aravantinos, A. Polyzos, P. Papakotoulas, g. Fountzilias, A. Potamianou, N. Ziras, J. Boukovinas, J. Varthalitis, N. Androulakis, **A. Kotsakis**, G. Samonis, V. Georgoulas: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. *Br J Cancer* 95: 587-592, 2006.
20. AG. Pallis, Ch. Christofillakis, E. Tselepatiotis, S. Agelaki, L. Vamvakas, J. Souglakos, N. Vardakis, A. Kalykaki, **A. Kotsakis**, A. Argiraki, D. Mavroudis, V. Georgoulas: Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. *Lung Cancer* 55: 101-107, 2006.
21. **A. Kotsakis**, Ch. Kouroussis, N. Androulakis, S. Agelaki, K. Kalbakis, L. Vamvakas, N. Vardakis, A. Kalykaki, A. Polyzos, V. Georgoulas, D. Mavroudis: A Dose Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors. *Oncology* 71: 190-196, 2006.

22. M. Ignatiadis, A. Polyzos, GP. Stathopoulos, E. Tselepatiotis, Ch. Christophylakis, K. Kalbakis, L. Vamvakas, **A. Kotsakis**, A. Potamianou, V. Georgoulas: A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. *Oncology* 71: 159-163, 2006.
23. Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, **Kotsakis A**, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulas V. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. *Oncology*. 2006; 70(4):306-14.
24. J. Souglakos, A. Kalykaki, L. Vamvakas, N. Androulakis, K. Kalbakis, S. Agelaki, N. Vardakis, M. Tzardi, **A. Kotsakis**, J. Gioulbasanis, D. Tsetis, G. Sfakiotaki, D. Hatzidaki, D. Mavroudis, V. Georgoulas: Phase II study Capecitabine and Oxaliplatin (CAPOX) plus Cetuximab is an effective treatment for patients with metastatic colorectal cancer who progressed after oxaliplatin- based chemotherapy. *Ann Oncol* 18: 305-310, 2007.
25. S. Apostolaki, M. Perraki, A. Pallis, V. Bozionelou, S. Agelaki, P. Kanellou, **A. Kotsakis**, E. Politaki, K. Kalbakis, A. Kalykaki, L. Vamvakas, V. Georgoulas, D. Mavroudis: Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. *Ann Oncol* 18: 851-858, 2007.
26. E. Bolonaki, **A. Kotsakis**, E. Papadimitraki, D. Agouraki, G. Konsolakis, A. Vagia, Ch. Christophylakis, E. Nikoloudi, E. Magganas, A. Galanis, P. Cordopatis, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis. Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001) *J Clin Oncol* 25: 2727-2734, 2007.
27. I. Gkioulbasanis, J. Souglakos, N. Vardakis, **A. Kotsakis**, Z. Saridaki, N. Kentepozidis, A. Polyzos, S. Giassas, M. Ignatiadis, V. Bozionelou, C. Christophylakis, V. Georgoulas Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract. *J BUON* 12: 197-202, 2007.
28. Ch. Emmanouilides, G. Sfakiotaki, N. Androulakis, K. Kalbakis, Ch. Christophylakis, A. Kalykaki, L. Vamvakas, **A. Kotsakis**, S. Agelaki, E. Diamandidou, N. Touroutoglou, A. Chatzidakis, V. Georgoulas, D. Mavroudis, J.Souglakos: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study *BMC* 7: 91, 2007.
29. Z. Saridaki, V. Bozionelou, N. Kentepozidis, **A. Kotsakis**, N. Vardakis, A. Kalykaki, I. Gioulbasanis, A. Karabeazis, L. Vamvakas, V. Georgoulas, D. Mavroudis: A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors. *Oncology* 72: 45-50, 2007.
30. V. Georgoulas, N. Androulakis, **A. Kotsakis**, D. Hatzidaki, K. Syrigos, A. Polyzis, A. Agelidou, I. Varthalitis, N. Ziras, M. Agelidou, V. Chandrinos, I. Boukovinas, A.

Geroyianni, L. Vamvakas, D. Mavroudis: Docetaxel versus docetaxel plus gemcitabine as front line treatment of patients with advanced non-small cell lung cancer: A randomized. Multicenter phase III trial. *Lung Cancer* 59: 57-63, 2008.

31. A. Kalykaki, P. Papakotoulas, S. Tsousis, I. Boukovinas, L. Vamvakas, **A. Kotsakis**, N. Vardakis, P. Papadopoulou, V. Georgoulas, D. Mavroudis: Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Anticancer Research* 28: 495-500, 2008.
32. A.G. Pallis, S. Agelaki, S. Kakolyris, **A. Kotsakis**, A. Kalykaki, N. Vardakis, P. Papakotoulas, A. Agelidou, A. Geroyianni, M. Agelidou, D. Hatzidaki, D. Mavroudis, V. Georgoulas: Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small-cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. *Lung Cancer* 62: 356-363, 2008.
33. I. Boukovinas, J. Souglakos, D. Hatzidaki, S. Kakolyris, N. Ziras, L. Vamvakas, A. Polyzos, A. Geroyianni, A. Agelidou, S. Agelaki, K. Kalbakis, **A. Kotsakis**, D. Mavroudis, V. Georgoulas: Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. *Lung Cancer* 63: 77-82, 2008.
34. S. Apostolaki, M. Perraki, G. Kallergi, M. Kafousi, S. Papadopoulou, **A. Kotsakis**, A. Pallis, N. Xenidis, L. Kalmanti, K. Kalbakis, S. Agelaki, S. A. Kalykaki, Ch. Stournaras, E. Stathopoulos, V. Georgoulas, D. Mavroudis: Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. *Breast Cancer Res Treat* 117:525-534, 2009.
35. Z. Saridaki, P. Pappas, J. Souglakos, M. Nikolaidou, N. Vardakis, **A. Kotsakis**, M. Marselos, V. Georgoulas, D. Mavroudis: A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. *Cancer Chemoth Pharm* 65: 121-128, 2009.
36. Ch. Kouroussis, L. Vamvakas, N. Vardakis, **A. Kotsakis**, A. Kalykaki, K. Kalbakis, Z. Saridaki, N. Kentepozidis, S. Giassas, V. Georgoulas: Continuous administration of daily low dose of temozolomide in pre-treated patients with advanced non-small cell lung cancer: A phase II study. *Oncology* 76: 112-117, 2009.
37. S. Agelaki, D. Hatzidaki, **A. Kotsakis**, P. Papakotoulas, A. Polyzos, N. Ziras, I. Gioulbasanis, A. Karampeazis, A. Agelidou, X. Tsiadaki, V. Chandrinou, M. Lerikou, V. Georgoulas: Non-platinum-based first-line followed by platinum-based second line chemotherapy of the reverse sequence in patients with advanced non-small cell lung cancer (NSCLC). A retrospective analysis by Lung Cancer Group of the Hellenic Oncology Research Group (HORG). *Oncology* 78: 229-236, 2010
38. N. Xenidis, **A. Kotsakis**, A. Kalykaki, C. Christophyllakis, S. Giassas, N. Kentepozidis, A. Polyzos, L. Chelis, N. Vardakis, L. Vamvakas, V. Georgoulas, S. Kakolyris: Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. *Lung Cancer* 68: 450-454, 2010.

39. **A.Kotsakis**, V. Georgoulas: Targeting epidermal growth factor receptor in the treatment of non-small cell lung cancer. *Expert Opin Pharmacoth* 11: 1-27, 2010.
40. S. Baka, S. Agelaki, **A. Kotsakis**, M. Veslemes, P. Papakotoulas, M. Agelidou, A. Agelidou, E. Tsaroucha, G. Pavlakou, A. Gerogianni, N. Androulakis, L. Vamvakas, K. Kalbakis, D. Mavroudis, V. Georgoulas: Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. *Anticancer Res* 30: 3031-3038, 2010.
41. **A. Kotsakis**, D. Hatzidaki, L. Vamvakas, N. Vardakis, A. Kalykaki, V. Bozionelou, N. Androulakis, K. Kalbakis, Z. Saridaki, V. Georgoulas, S. Agelaki: A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. *Anticancer Res* 30: 4335-4342, 2010.
42. **A. Kotsakis**, S. Agelaki, N. Vardakis, G. Stathopoulos, L. Vamvakas, A. Kalykaki, N. Kentepozidis, E. Kontopodis, G. Sfakiotaki, D. Mavroudis, V. Georgoulas: A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. *Cancer Chemother Pharmacol* 68: 415-22, 2010.
43. AG. Pallis, S. Agelaki, A. Agelidou, I. Varthalitis, K. Syrigos, N. Kentepozidis, G. Pavlakou, **A. Kotsakis**, E. Kontopodis, V. Georgoulas: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer. *BMC Cancer* 10: 633-641, 2010.
44. Tarhini A, **Kotsakis A**, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. *Clin Cancer Res*. 2010 Dec 1;16(23):5900-7.
45. A.G. Pallis, K. Syrigos, **A. Kotsakis**, N. Karachaliou, A. Polyzos, V. Chandrinou, I. Varthalitis, Ch. Christophyllakis, A. Ardavanis, L. Vamvakas, N. Vardakis, Z. Saridaki, G. Samonis, S. Giassas, V. Georgoulas, S. Agelaki: Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients with advanced non-small cell lung cancer pre-treated with non-platinum-based chemotherapy: A multicenter randomized phase II study. *Clinical Lung Cancer* 12: 100-105, 2011.
46. AG. Pallis, A. Karampeazis, L. Vamvakas, N. Vardakis, **A. Kotsakis**, V. Bozionelou, A. Kalykaki, D. Hatzidaki, D. Mavroudis, V. Georgoulas. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. *Ann Oncol*. 2011 Nov;22(11):2448-55.
47. EK. Vetsika, E. Papadimitraki, D. Aggouraki, G. Konsolakis, ME. Mela, **A. Kotsakis**, S. Christou, S. Patramani, M. Alefantinou, A. Kaskara, C. Christophyllakis, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis: Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients. *J Immunother* 34: 641-50, 2011.
48. AG. Pallis, A. Voutsina, N. Kentepozidis, S. Giassas, P. Papakotoulas, S. Agelaki, K.

- Tryfonidis, **A. Kotsakis**, L. Vamvakas, N. Vardakis, V. Georgoulas: A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2012 Mar;13(2):129-35.
49. Argiris A, Karamouzis MV, Smith R, **Kotsakis A**, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. *Ann Oncol*. 2011 Nov;22(11):2482-8.
  50. I. Boukovinas, N. Androulakis, N. Kentepozidis, A. Polyzos, P. Papakotoulas, N. Ziras, **A. Kotsakis**, N. Vardakis, A. Karampeazis, V. Markos, A. Kostakopoulos, CA. Constantinides, G. Samonis, D. Mavroudis, V. Georgoulas: Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Cancer Chemother Pharmacol*. 2012 Feb;69(2):351-6.
  51. EK Vetsika, G. Konsolakis, D. Aggouraki, **A. Kotsakis**, E. Papadimitraki, S. Christou, J. Menez-Jamet, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis: Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. *Cancer Immunol Immunother*. 2012 Feb;61(2):157-68.
  52. **A. Kotsakis**, EK. Vetsika, S. Christou, D. Hatzidaki, N. Vardakis, D. Aggouraki, G. Konsolakis, V. Georgoulas, C. Christophyllakis, P. Cordopatis, K. Kosmatopoulos, D. Mavroudis: Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. *Ann Oncol*. 2012 Feb;23(2):442-9.
  53. Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, **Kotsakis A**, Agelidou M, Georgoulas V. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. *Lung Cancer*. 2012 Jul;77(1):146-50.
  54. **Kotsakis A**, Harasymczuk M, Schilling B, Georgoulas V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. *J Immunol Methods*. 2012 Jul 31;381(1-2):14-22.
  55. Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, **Kotsakis A**, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulas V. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. *Cancer Chemother Pharmacol*. 2012 Jul;70(1):161-8.
  56. Argiris A, **Kotsakis AP**, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. *Ann Oncol*. 2013 Jan;24(1):220-5.
  57. Kentepozidis N, **Kotsakis A**, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulas V.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. *Cancer Chemother Pharmacol.* 2013 Mar;71(3):605-12.

58. Huang D, Kim DW, **Kotsakis A**, Deng S, Lira P, Ho S, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. *Genomics.* 2013 Feb 20. doi:pii: S0888-7543(13)00034-7. 10.1016/j.ygeno.2013.02.006. [Epub ahead of print]
59. Agelaki S, Kontopodis E, **Kotsakis A**, Chandrinou V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulas V. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. *Cancer Chemother Pharmacol.* 2013 Apr 21. [Epub ahead of print]
60. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, **Kotsakis A**, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulas V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. *Cancer.* 2013 May 9. doi: 10.1002/cncr.28132. [Epub ahead of print]
61. Ramalingam SS, **Kotsakis A**, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A. A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. *Lung Cancer.* 2013 Jul 10. [Epub ahead of print]
62. Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, **Kotsakis A**, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulas V. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *Cancer Chemother Pharmacol.* 2014 Jun 15. [Epub ahead of print]



## **IMPACT FACTOR IN INTERNATIONAL JOURNALS**

Total Impact Factor	209.154
Average Impact Factor	3.373
h-index	17

\* Data from research (2013) in each journal separately (impact factor-Journal-home page)

## **CITATION INDEX**

### **IST Web of Science**

<b>Results found:</b>	
Sum of the Times Cited	1090
Sum of Times Cited without self-citations	1065
Citing Articles	994
Citing Articles without self-citations	977
Average Citations per Item	11.72
h-index	17

## ABSTRACTS IN INTERNATIONAL CONGRESSES

### *Abstracts, Posters, Oral Presentations*

1. S. Papadaki, E. Sarra, Ch. Kouroussis, **Th. Kotsakis**, L. Vamvakas, E. Stefanaki, E. Mavromanolakis, J.Vlachonicolis, V.Georgoulas: Lymphocyte abnormalities during post-chemotherapy myelosuppression and bone marrow regeneration in patients with solid tumors  
*7<sup>th</sup> International Congress on anti-cancer treatment, Paris Febr.1997*
2. Ch. Kouroussis, N. Androulakis, S. Kakolyris, V. Papoutsakis, P. Herras, N. Vardakis, **A. Kotsakis**, K. Kalbakis, N. Meramveliotakis, G. Fytrolakis, E. Stefanakis, D. Hadzidaki, G. Samonis, V. Georgoulas: Phase I study of alternating docetaxel and mitoxantrone with G-CSF support in advanced breast cancer  
*33rd ASCO May 1997, Denver, USA*
3. E. Papadakis, Ch. Kouroussis, S. Kakolyris, N. Androulakis, A. Dimopoulos, S. Tzannes, **A. Kotsakis**, N. Vardakis, K. Kalbakis, N. Meramveliotakis, D. Hadzidaki, V. Georgoulas: Second line treatment of advanced NSCLC after cisplatin-based chemotherapy with paclitaxel and gemcitabine  
*8<sup>th</sup> World Conference on Lung Cancer, August 1997, Dublin Ireland*
4. Ch. Kouroussis, N. Androulakis, S. Kakolyris, P. Herras, N. Vardakis, **Ath. Kotsakis**, K. Kalbakis, N. Meramveliotakis, D. Hadzidaki, G. Samonis, V. Georgoulas: Phase I/II study of alternative docetaxel and mitoxantrone with G-CSF support in advanced breast cancer  
*ECCO 9<sup>th</sup> , 14-18 September 1997, Hamburg Germany*
5. S. Kakolyris, Ch. Kouroussis, N. Androulakis, M. Dimopoulos, E. Papadakis, S. Tzannes, **Th. Kotsakis**, N. Vardakis, N. Meramveliotakis, K. Kalbakis, D. Hatzidaki, V. Georgoulas: Second line treatment of non small cell lung cancer with paclitaxel and gemcitabine  
*ECCO 9<sup>th</sup> , 14-18 September 1997, Hamburg Germany*
6. Ch. Kouroussis, N. Androulakis, J. Souglakos, S. Kakolyris, **Ath. Kotsakis**, A. Dimopoulos, K. Kalbakis, K. Katsogridakis, G. Prinianakis, G. Samonis, V. Georgoulas: Acute inflammatory abdominal events complicating taxane-based chemotherapy: a report of four cases  
*8<sup>th</sup> International Congress on Anti-Cancer Treatment Febr,1998 Paris. France*

7. D. Mavroudis, Ch. Kouroussis, N. Malamos, A. Potamianos, S. Kakolyris, N. Androulakis, E. Papadakis, K. Kalbakis, S. Aggelaki, **Th. Kotsakis**, J. Souglakos, V. Georgoulas: A phase II trial of docetaxel and gemcitabine as second line treatment in advanced breast cancer  
*8<sup>th</sup> International Congress on Anti-Cancer Treatment Febr, 1998 Paris France*
  
8. S. Kakolyris, Ch. Kouroussis, N. Androulakis, J. Souglakos, D. Mavroudis, K. Kalbakis, S. Aggelaki, **Ath. Kotsakis**, G. Prinianakis, N. Vardakis, V. Georgoulas : Phase I study of cisplatin and irinotecan(CPT-11) Combination in metastatic non-small cell lung cancer  
*8<sup>th</sup> International Congress on Anti-Cancer Treatment Febr,1998 Paris, France*
  
9. S.Kakolyris,Ch.Kouroussis,J.Souglakos,N.Androulakis, D.Mavroudis, K. Kalbakis, **Ath.Kotsakis**, E.Sarra, S.Aggelaki,G.Prinianakis,N.Vardakis G.Samonis,V.Georgoulas : Phase I study of CPT-11 and CDDP combination in metastatic NSCLC  
*34<sup>rd</sup> ASCO, May 1998, (abs 1884)*
  
10. V. Georgoulas, Ch. Kouroussis, N. Androulakis, S. Kakolyris, A. Dimopoulos, E. Papadakis, Ch. Papadimitriou, K. Hatzakis, E. Bania, F. Apostolopoulou, Ch. Tsiadaki, A. Alexopoulos, J. Souglakos, **Th. Kotsakis**, J. Vlachonikolis, D. Hadzidaki: Front line treatment at NSCLC with docetaxel and gemcitabine  
*34<sup>rd</sup> ASCO, May 1998, (abs.1819)*
  
11. V. Georgoulas, N. Androulakis, Ch. Kouroussis, S. Kakolyris, E. Papadakis, M. Aggelidou, G. Blazoyannakis, A. Gerogiannis, M. Velsemes, A. Aggelidou, A. Dimopoulos, **Th. Kotsakis**, J. Souglakos, D. Hadzidaki: Second line treatment with paclitaxel and gemcitabine in patients with non-small cell lung cancer who failed cisplatin based chemotherapy  
*34<sup>rd</sup> ASCO, May 1998, (abs.1800)*
  
12. S. Kakolyris, N. Androulakis, J. Souglakos, Ch. Kouroussis, K. Kalbakis, **Ath. Kotsakis**, S. Aggelaki, D. Hadzidaki, G. Samonis, V. Georgoulas: Phase I study with irinotecan(CPT-11) plus 5-FU combination in advanced colon cancer  
*34<sup>rd</sup> ASCO, May 1998, (abs.1070)*
  
13. Ch. Kouroussis, S. Kakolyris, E. Samelis, G. Aravantinos, A.M. Dimopoulos, Ch. Papadimitriou, D. Genatas, N. Tzavaris, S. Karambekios, G. Stathopoulos, **Th. Kotsakis**, J. Souglakos, G. Samonis, V. Georgoulas: Treatment of advanced pancreatic cancer(APC) with docetaxel. A multicenter phase II study.

*Proceedings ASCO- The 34rd. Annual Meeting, May 1998, Los Angeles (abs n.1021)*

14. D. Mavroudis, Ch. Kouroussis, N. Malamos, A. Potamianou, S. Kakolyris, A. Alexopoulos, N. Androulakis, E. Papadakis, J. Vlachonikolis, K. Kalbakis, S. Aggelaki, **Th. Kotsakis**, E. Sarra, J. Souglakos, G. Samonis, V. Georgoulis: A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer  
*Proceedings ASCO- The 34rd. Annual Meeting, May 1998, Los Angeles (abs n.607)*
15. Malamos N, Alexopoulos A, Mavroudis D, Kouroussis Ch, Potamianou A, Kakolyris S, Androulakis N, Papadakis E, Vlachonikolis J, Kalbakis K, Agelaki S, **Kotsakis Th**, Sara E, Souglakos J, Samonis G, Georgoulis V: A phase ii trial of Docetaxel and Gemcitabine as second line treatment in metastatic Breast Cancer.  
*17th International Cancer Congress, August 23–28, 1998, Rio de Janeiro*
16. V. Georgoulis, Ch. Kouroussis, N. Androulakis, S. Kakolyris, M.A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, Ch. Papadimitriou, A. Aggelidou, V. Tzianni, F. Apostolaki, K. Hatzakis, K. Kalbakis, **Ath. Kotsakis**, E. Sarra, N. Vardakis, J. Vlachonikolis: Front line treatment of advanced non small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial  
*5<sup>th</sup> Central European Lung Cancer Conference, Sept.1998, Prague*
17. S. Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D. Mavroudis, K. Kalbakis, **Ath. Kotsakis**, E. Sarra, S. Aggelaki, G. Prinianakis, N. Vardakis, G. Samonis, V. Georgoulis: Phase I study of irinotecan(CPT-11) and Cisplatin (CDDP) combination in metastatic non small cell lung cancer  
*5<sup>th</sup> Central European Lung Cancer Conference, Sept.1998, Prague*
18. N. Androulakis, Ch. Kouroussis, S. Kakolyris, S. Tzannes, E. Papadakis, Ch. Papadimitriou, A. Gerogianni, Th. Georgopoulou, I. Dimopoulou, J. Souglakos, V. Tzianni, F. Apostolaki, **Ath. Kotsakis**, N. Vardakis, T. Kalikaki, D. Hadzidaki, V. Georgoulis: Salvage treatment with paclitaxel and gemcitabine for patients with non small lung cancer after Cisplatin or docetaxel-based chemotherapy. A multicenter phase II trial  
*5<sup>th</sup> Central European Lung CancerConference, Sept.1998, Prague*
19. V. Georgoulis, Ch. Kouroussis, N. Androulakis, S. Kakolyris, M.A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou,

- Ch. Papadimitriou, A. Aggelidou, V. Tzianni, F. Apostolaki, K. Hatzakis, K. Kalbakis, **Ath. Kotsakis**, E. Sarra, N. Vardakis, J. Vlachonikolis: Front line treatment of advanced non small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial  
*3<sup>rd</sup> International Congress on Lung Cancer, October 1998, Rhodes*
20. S. Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D. Mavroudis, K. Kalbakis, **Ath. Kotsakis**, E. Sarra, S. Aggelaki, G. Prinianakis, N. Vardakis, G. Samonis, V. Georgoulas : Phase I study of irinotecan(CPT-11) and Cisplatin (CDDP) combination in metastatic non small cell lung cancer  
*3<sup>rd</sup> International Congress on Lung Cancer, October 1998 Rhodes*
21. N. Androulakis, Ch. Kouroussis, S. Kakolyris, S. Tzannes, E. Papadakis, Ch. Papadimitriou, A. Gerogianni, Th. Georgopoulou, I. Dimopoulou, J. Souglakos, V. Tzianni, F. Apostolaki, **Ath. Kotsakis**, N. Vardakis, T. Kalikaki, D. Hadzidaki, V. Georgoulas: Salvage treatment with paclitaxel and gemcitabine for patients with non small lung cancer after Cisplatin or docetaxel-based chemotherapy. A multicenter phase II trial  
*3<sup>rd</sup> International Congress on Lung Cancer, October 1998 Rhodes*
22. V. Georgoulas, S. Papadaki, E. Sarra, C. Kouroussis, **T. Kotsakis**, L. Vamvakas, , E. Stefanakis, E. Mavromanolakis, J. Vlachonikolis: Lymphocyte abnormalities during post-chemotherapy myelosuppression and bone marrow regeneration in patients with Solid Tumors.  
*ECCO (European Conference on Clinical Oncology ), 6-10 Nov. 1998, Athens*
23. S. Kakolyris, C. Kouroussis, N. Androulakis, M. A. Dimopoulos, E. Papadakis, S. Tzannes, **T. Kotsakis**, N. Vardakis, N. Merambeliotakis, C. Kalbakis, D. Xatzidaki, V. Georgoulas: Second line treatment of Non - small cell lung cancer with paclitaxel and gemcitabine.  
*ECCO (European Conference on Clinical Oncology ), 6-10 Nov. 1998, Athens*
24. C.Kouroussis, N.Androulakis, S.Kakolyris, P.Heras, N.Vardakis, **A.Kotsakis**, C.Kalbakis, N.Meramveliotakis, D.Hatzidaki, G.Samonis and V.Georgoulas: phase I/II study of alternating docetaxel and mitoxantrone with g-csf support in advanced breast cancer (abc).  
*ECCO (European Conference on Clinical Oncology ), 6-10 Nov. 1998, Athens*
25. S. Kakolyris, Ch. Kouroussis, J. Souglakos, N. Androulakis, D.

- Mavroudis, K. Kalbakis, **Ath. Kotsakis**, E. Sarra, S. Aggelaki, G. Prinianakis, N. Vardakis, G. Samonis, V. Georgoulas: Phase I study of CPT-11 and CDDP combination in metastatic NSCLC  
*23<sup>th</sup> ESMO Congress, 6 Nov-15 Nov 1998, Lugano*
26. V. Georgoulas, Ch. Kouroussis, E. Papadakis, S. Kakolyris, M.A. Dimopoulos, F. Apostolopoulou, X. Tsiadaki, E. Bania, V. Tzianni, **A. Kotsakis**, E. Sarra, N. Vardakis: Efficacy of docetaxel/gemcitabine combination as first line treatment of non-smallcell lung cancer  
*9<sup>th</sup> International Congress on anti-cancer treatment February 1999, Paris, France*
27. J. Souglakos, **A. Kotsakis**, E. Sarra, S. Kakolyris, Ch. Kouroussis, S. Aggelaki, N. Vardakis, K. Kalbakis, V. Georgoulas: Non neutropenic infections associated with docetaxel containing chemotherapy in patients with solid tumors  
*ECCO (European Conference on Clinical Oncology )-10, Vienna 12-16 Sept 1999*
28. N. Androulakis, **A. Kotsakis**, N. Kentepozidis, Z. Saridaki, T. Kokkinakis, N. Katsougris, G. Milaki, L. Vamvakas, Ch. Kouroussis, V. Georgoulas: Phase I study of alternating Oxaliplatin (OXA) with Irinotecan (IRI) in combination with weekly Leucovorin (LV)-modulated continuous infusion 5-Fluorouracil (5-FU) in patients with gastrointestinal malignancies: Final results.  
*15<sup>th</sup> International Congress on Anti-cancer Treatment Febr.9-12 2004- Paris-France*
29. J. Souglakos, Z. Saridaki, A. Pallis, L. Vamvakas, K. Kalbakis, D. Mavroudis, G. Milaki, **A. Kotsakis**, M. Ignatiadis, V. Georgoulas: Combination of Irinotecan (CPT-11) and Gefinitib (zd1839) for patients with metastatic colorectal cancer (MCC) refractory to Irinotecan-based 1st line chemotherapy: A pilot phase II study  
*GI, 2004, Barcelona*
30. J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, J. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, **Ath. Kotsakis**, V. Georgoulas: Combination of Irinotecan (CPT-11) plus Oxaliplatin(L-OHP), as first line treatment in locally advanced or metastatic gastric cancer: A multicenter phase II trial  
*15<sup>th</sup> International Congress on Anti-cancer Treatment Febr.9-12 2004- Paris-France*
31. A. Potamianou, A. Polyzos, J. Boukovinas, Ch. Latoufis, N.

- Androulakis, S. Aggelaki, **A. Kotsakis**, S. Giassas, L. Vamvakas, J. Varthalitis: Sequential combination of paclitaxel-carboplatin and paclitaxel- liposomal doxorubicin as first line treatment in patients with ovarian cancer: A multicenter phase II clinical trial  
*40<sup>th</sup> ASCO, June 5-8 2004- USA*
32. A. Polyzos, D. Mavroudis, J. Boukovinas, E. Tsiakopoulos, N. Malamos, G. Milaki, C. Kouroussis, **A. Kotsakis**, A. Pallis, V. Georgoulas:  
For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece: A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) over expressing HER-2.  
*40<sup>th</sup> ASCO, June 5-8 2004- USA*
33. N. Androulakis, Ch. Kouroussis, J. Souglakos, L. Vamvakas, D. Mavroudis, N. kentepozidis, **A. Kotsakis**, L. Hellis, Ch. Mikropoulos, M. Ignatiadis, Ch. Fotiou, V. Georogulias: Irinotecan (CPT-11) plus weekly 5-Fluorouracil (5-FU) and Leukovorin (LV) as salvage treatment for patients with metastatic colorectal cancer (MCC): A phase II trial.  
*Journal of BUON, 14-19 October 2004, Belgrade*
34. A. Athanasiadis, J. Souglakos, A. Polyzos, A. Ardavanis, A. Potamianou, E. Tselepatiotis, **A. Kotsakis**, N. Androulakis, A. Kalikaki: Preliminary results of phase II study with XELOX as salvage treatment for patients with metastatic colorectal cancer (MCC) pretreated with FOLFIRI  
*29<sup>th</sup> ESMO Congress, 29 Oct-2 Nov 2004 Vienna, Austria*
35. J. Boukovinas, N. Androulakis, A. Potamianou, N. Ziras, K. Kalbakis, P. Papakotoulas, T. Kalykaki, Ch. Kouroussis, **A. Kotsakis**, V. Bozionelou, M. Ignatiadis, V. Georgoulas: Sequential administration of Cisplatin+Gemcitabine and Docetaxel as first line treatment in patients with bladder cancer. A multicenter phase II trial  
*16<sup>th</sup> International Congress on Anti-cancer Treatment, 1-4 February 2005, Paris*
36. V. Georgoulas, A. Ardavanis, M. Agelidou, A. Agelidou, J. Boukovinas, P. Papakotoulas, P. Ziotopoulos, M. Toubis, K. Syrigos, A. Polyzos, S. Kakolyris, Ch. Kouroussis, N. Androulakis, **A. Kotsakis**, S. Agelaki, G. Samonis, D. Chatzidaki: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial  
*16<sup>th</sup> International Congress on Anti-cancer Treatment, 1-5*

February 2005, Paris

37. Souglakos J, Androulakis N, Tzardi M, Kalikaki A, Argyraki A, Vardakis N, Sfakiotaki G, **Kotsakis A**, Mavroudis D, Georgoulas V: Dept of Medical Oncology, University General Hospital of Heraklion, Crete, Greece: Cetuximab plus capecitabine(CAP)and oxaliplatin(L-OHP)(CAPOX) in cancer(mCRC) who failed on oxiplatin-based chemotherapy.  
*GI, 15-18 June 2005 Barcelona, Spain*
38. N. Kentepozidis, S. Aggelaki, L. Vamcakas, **A. Kotsakis**, Z. Saridaki, J. Gioulbasakis, A. Kalikaki, M. Ignatiadis, G. Sfakiotaki, D. Mavroudis: Dept of Medical Oncology, University General Hospital of Heraklion, Greece : First line treatment with docetaxel and cisplatin in non-small cell lung cancer patients: A retrospective analysis  
*IASLC, 11<sup>th</sup> World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain*
39. I. Boukovinas, N. Androulakis, A. Kalykaki, I. Souglakos, V. Bozionelou, A. Pallis, N. Vardakis, **A. Kotsakis**, S. Giassas, V. Georgoulas: A phase II study with docetaxel and gemcitabine in previously untreated patients with advanced lung adenocarcinomas.  
*IASLC, 11<sup>th</sup> World Conference on Lung Cancer, 1-6 July 2005, Barcelona, Spain*
40. I. Boukovinas, N. Ziras, A. Kalikaki, A. Ardavanis, A. Polyzos, C. Christophylakis, A. Pallis, **A. Kotsakis**, S. Giassas, V. Georgoulas: (HORG): The Lung Cancer Working Group. The Hellenic Oncology Research Group, Heraklion, Greece : A multicenter Phase II study with docetaxel plus gemcitabine in untreated patients with advanced lung adenocarcinomas  
*ECCO (European Conference on Clinical Oncology ), 30 Oct-3 Nov 2005 , Paris, France*
41. D. Mavroudis, J. Souglakos, A. Kalikaki, N. Androulakis, S. Aggelaki, **A. Kotsakis**, N. Vardakis, K. Kalbakis, V. Georgoulas: University General Hospital, Dept of Medical Oncology, Heraklion, Greece : A phase I/II study of imatinib mesylate(glivec) in combination with irinotecan(CPT-11) in patients with relapsed or refractory small cell lung cancer(SCLC)  
*ECCO (European Conference on Clinical Oncology ), 30 Oct-3 Nov 2005, Paris, France*
42. A. Kalikaki, A. Potamianou, N. Malamos, K. Syrigos, K. Kalbakis, N. Androulakis, L. Vamvakas, V. Bozionelou, **A. Kotsakis**, D. Mavroudis; Breast Cancer Group, of the Hellenic Oncology Research Group(HORG) Heraklion, Greece:



Gemcitabine(GEM) plus Oxaliplatin(LOHP) as salvage treatment in anthracycline and taxane pretreated patients with advanced breast cancer(ABC)

*ECCO (European Conference on Clinical Oncology ) , 30 Oct-3 Nov 2005,Paris, France*

43. Souglakos J,Androulakis N, Tzardi M, Kalikaki A, Argyraki A, Vardakis N, Sfakiotaki G, **Kotsakis A**, Mavroudis D, Georgoulas V: Dept of Medical Oncology, University General Hospital of Heraklion,Crete, Greece: Cetuximab plus capecitabine(CAP)and oxaliplatin(L-OHP)(CAPOX) in cancer(mCRC) who failed on oxiplatin-based chemotherapy.  
*17<sup>th</sup> International Congress on Anti-cancer Treatment, 30/1- 4/2 2006, Paris, France*
44. C. Emmanouilides, G. Sfakiotaki, J. Souglakos, D. Mavroudis, N. Androulakis, A. Kalykaki, **A. Kotsakis**, K. Kalbakis, E. Diamandidou, N. Touroutoglou, V. Georgoulas: Bevacizumab plus oxaliplatin (LOHP), leukovorin (LV)/5-fluorouracil (5-FU) (FOLFOX4) as first line treatment of patients with metastatic colorectal cancer (MCC).  
*17<sup>th</sup> International Congress on Anti-cancer Treatment, 30/1- 4/2 2006, Paris, France*
45. AG. Pallis, A. Agelidou, P. Papakotoulas, A. Tsaroucha, M. Agelidou, S. Agelaki, N. Androulakis, L. Vamvakas, A. Gerogianni, **A. Kotsakis**, N. Kentepozidis, V. Georgoulas: A Multicenter Phase II study of sequential Vinorelbine and Cisplatin followed by Docetaxel and Gemcitabine in patients with Advanced non-small Cell Lung Cancer  
*17<sup>th</sup> International Congress on Anti-cancer Treatment, 30/1- 4/2 2006, Paris, France*
46. Souglakos J, Androulakis N, Tzardi M, Kalikaki A, Argyraki A, Vardakis N, Sfakiotaki G, **Kotsakis A**, Mavroudis D, Georgoulas V: Dept of Medical Oncology, University General Hospital of Heraklion,Crete, Greece: Cetuximab plus capecitabine(CAP)and oxaliplatin(L-OHP)(CAPOX) in cancer(mCRC) who failed on oxiplatin-based chemotherapy.  
*42<sup>nd</sup> ASCO-GI, 2-6 June 2006 Atlanta, USA*
47. A. Kalikaki, S. Aggelaki, K. Kalbakis, **A. Kotsakis**, N. Kentebozidis, C. Christophylakis, S. Giassas, L. Vamvakas, N. Vardakis, D. Mavroudis: University General Hospital, Heraklion, Greece : Phase I study of gemcitabine(GEM) and premetrexed(ptx) In the treatment of advanced solid tumors.  
*42<sup>nd</sup> ASCO-GI, 2-6 June 2006 Atlanta, USA*
48. K. Kosmatopoulos, E. Bolonaki, D. Aggouraki, E. Nikoloudi, P.

Kannelou, E. Papadimitraki, **A. Kotsakis**, D. Mavroudis, V. Georgoulas: Vaxon Biotech, Evry Genopole, France; University General Hospital, Heraklion, Greece: Clinical efficacy and immunogenicity of optimized cryptic peptide TERT572 vaccine(Vx-001) in patients with advanced non-small cell lung cancer(NSCLC)

*42<sup>nd</sup> ASCO-GI, 2-6 June 2006 Atlanta, USA*

49. A. G. Pallis, S. Agelaki, S. Kakolyris, **A. Kotsakis**, A. Kalykaki, N. Vardakis, P. Papakotoulas, A. Agelidou, A. Geroyianni, M. Agelidou, D. Hatzidaki, D. Mavroudis, V. Georgoulas: Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small-cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.  
*18<sup>th</sup> International Congress on Anti-cancer Treatment, 6-13 February 2007, Paris, France*
50. **A. Kotsakis**, Ch. Kouroussis, N. Androulakis, J. Souglakos, K. Kalbakis, L. Vamvakas, N. Vardakis, A. Kalykaki, V. Markos, J. Gioulbasanis: A Dose Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors  
*18<sup>th</sup> International Congress on Anti-cancer Treatment, 6-13 February 2007, Paris, France*
51. A. Pallis, S. Apostolaki, M. Perraki, L. Kalmanti, N. Xenidis, V. Bozionellou, K. Kalbakis, **A. Kotsakis**, S. Agelaki, M. Ignatiadis, Z. Saridaki, E. Stathopoulos, E. Lianidou, V. Georgoulas, D. Mavroudis: HER2 mRNA-positive circulating tumor cells in patients with stage I and II breast cancer: evaluation of their prognostic significance.  
*18<sup>th</sup> International Congress on Anti-cancer Treatment, 6-13 February 2007, Paris, France*
52. S. Agelaki, N. Androulakis, A. Agelidou, M. Agelidou, **A. Kotsakis**, S. Kakolyris, A. Polyzos, N. Kentepozidis, N. Ziras, D. Mavroudis: Phase III randomized study of oral vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): A preliminary report.  
*43<sup>rd</sup> ASCO, 1-5 June 2007 Chicago, USA*
53. J Souglakos, K. Kalbakis, N. Vardakis, L. Vamvakas, A. Kalykaki, **A. Kotsakis**, S. Agelaki, A. Karampeazis, J. Gioulbasanis, V. Georgoulas: Cetuximab plus Bevacizumab in patients (pts) with metastatic colorectal cancer (mCRC) who have failed on Irinotecan, Oxaliplatin and Fluoropyrimidines-based chemotherapy  
*43<sup>rd</sup> ASCO, 1-5 June 2007 Chicago, USA*

54. Kosmatopoulos K, Bolonaki E, **Kotsakis A**, Papadimitraki E, Agouraki D, Konsolakis G, Vagia A, Christophylakis Ch, Georgoulas V, Mavroudis D: Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001)  
*43<sup>rd</sup> ASCO, 1-5 June 2007 Chicago, USA*
55. S. Agelaki, N. Androulakis, A. Agelidou, M. Agelidou, **A. Kotsakis**, S. Kakolyris, A. Polyzos, N. Kentepozidis, N. Ziras, D. Mavroudis: Phase III randomized study of oral vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): A preliminary report.  
*IASLC, 2-6 September 2007, Seoul*
56. L. Vamvakas, A. Karampeazis, S. Agelaki, A. Agelidou, **A. Kotsakis**, S. Kakolyris, A. Polyzos, A. Pallis, E. Saloustros, V. Georgoulas: Oral Vinorelbine and Gemcitabine (oVG) versus Docetaxel and Gemcitabine (DG) as first-line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A subgroup analysis for elderly patients of a phase III Randomized Trial from the Hellenic Oncology Research group:  
*SIOG, 8-12 November 2007, Madrid*
57. I.Gioulbasanis, L. Vamvakas, A. Karampeazis, N. Androulakis, K. Kalbakis, S. Agelaki, A. Kalykaki, **A. Kotsakis**, V. Georgoulas, D. Mavroudis; Prognostic role of baseline levels of chemokine IL-8 in metastatic lung cancer patients  
*IASLC, 24-26 April 2008, Geneva, Switzerland*
58. E.K. Vetsika, G. Konsolakis, E. Bolonaki, **A. Kotsakis**, E. Papadimitraki, N. Christou, M. Drogaris, D. Aggouraki, J. Menez-Jame, K. Kosmatopoulos, V. Georgoulas, D. Mavroudis: Immune responses in cancer patients after vaccination with the therapeutic telomerase –specific vaccine Vx-001.  
*AACR, 12-20 April 2008, San Diego, USA*
59. **A. Kotsakis**, K. Vetsika, N. Christou, M. Drogaris, N. Pantazopoulos, D. Agouraki, G. Konsolakis, K. Kosmatopoulos, D. Mavroudis, V. Georgoulas: Clinical and immunological response of patients with advanced solid tumors vaccinated with an optimized cryptic hTERT peptide (Vx-001).  
*44<sup>th</sup> ASCO, 30 May- 9 June 2008 Chicago, USA*
60. S. Baka, D. Mavroudis, A. Agelidou, M. Vaslemes, I. Boukovinas, N. Androulakis, **A. Kotsakis**, A. Gerogianni, X. Tsiafaki, V. Chardrinos: Comparison of the sequential versus the alternate administration of cisplatin-etoposide and

topotecan regimens as first line treatment in extensive stage small cell lung cancer (SCLC) - FINAL analysis of a multicenter trial.

*ESMO, 12-16 September 2008, Stockholm, Suede*

61. I. Gioulbasanis, Z. Giannousi, E. Saloustris, L. Vamvakas, A. Karampeazis, N. Androulakis, K. Kalbakis, **A. Kotsakis**, A. Kalykaki, N. Vardakis: Prognostic value of Mini Nutritional Assessment (MNA) Score in elderly lung-cancer patients  
*SIOG, 16-19 October 2008, Montreal, Canada*
62. E.K. Vetsika, D. Aggouraki, G. Konsolakis, **A. Kotsakis**, E. Papadimitraki, N. Christou, K. Kosmatopoulos, V. Georgoulis, D. Mavroudis: Immune response assessment in cancer patients vaccinated with Vx-001 vaccine.  
*Recent Advances in Cancer Immunotherapy with an Emphasis on Vaccines, 9-11 October 2008, Athens, Greece*
63. A. G. Pallis, S. Agelaki, S. Kakolyris, **A. Kotsakis**, A. Kalykaki, N. Vardakis, P. Papakotoulas, A. Agelidou, A. Geroyianni, M. Agelidou, D. Hatzidaki, D. Mavroudis, V. Georgoulis: Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small-cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.  
*19<sup>th</sup> International Congress on Anti-cancer Treatment, 5-12 February 2008, Paris, France*
64. **A. Kotsakis**, S. Agelaki, N. Vardakis, L. Vamvakas, A. Kalykaki, N. Kentepozidis, E. Kontopodis, G. Sfakiotaki, D. Mavroudis, V. Georgoulis: Phase I study of the combination of docetaxel (D) and pemetrexed (P) in patients with advanced unresectable or metastatic non small cell lung cancer (NSCLC)  
*ESMO, 20-24 September 2009, Stockholm, Berlin*
65. S. Agelaki, ED Kontopodis, N. Kentepozidis, S. Giassas, N. Vamvakas, N. Androulakis, **A. Kotsakis**, G. Sfakiotaki, D. Mavroudis, V. Georgoulis: A Phase II Trial of Low-dose Metronomic Oral Vinorelbine as Salvage Treatment in Advanced Non-Small Cell Lung Cancer (NSCLC)  
*IASLC, July 31-August 4 2009, San Francisco, USA*
66. S. Agelaki, N. Kentepozidis, S. Giassas, **A. Kotsakis**, K. Kalbakis, N. Androulakis, A. Kalykaki, E. Saloustris, G. Milaki, M. Rovithi, D. Mavroudis, V. Georgoulis: A prospective phase II trial of erlotinib as first-line treatment in Caucasian non- and ex-smokers with advanced lung adenocarcinomas  
*IASLC, July 31-August 4 2009, San Francisco, USA*
67. S. Agelaki, K. Syrigos, A. Polyzos, A. Agelidou, V. Handrinos, **A.**

- Kotsakis**, Ch. Christophyllakis, N. Vardakis, V. Georgoulas: A Multicenter Randomized Phase II Study of Paclitaxel (P) and Carboplatin (C) Versus Oral Vinorelbine (oV) and Carboplatin (C) as Second-line Treatment in Patients (pts) with Non-small Cell Lung Cancer (NSCLC) Pretreated with Non-platinum Based Chemotherapy  
*IASLC, July 31-August 4 2009, San Francisco, USA*
68. N Androulakis, V. Bozionelou, M. Perraki, S. Apostolaki, A. Kalykaki, K. Kalbakis, **A. Kotsakis**, D. Mavroudis, V. Georgoulas. Clinical relevance of circulating CK-19 mRNA-positive cells detected before and during front line chemotherapy in patients with metastatic breast cancer  
*IMPAKT, Brussels, May 7-9, 2009, Brussels, Belgium*
69. A.Kalykaki, S. Agelaki, **A. Kotsakis**, L. Vamvakas, V. Bozionelou, K. Kalbakis, N. Androulakis, V. Georgoulas, D. Mavroudis. A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.  
*45<sup>th</sup> ASCO, May 29- June 2, 2009 Chicago, USA*
70. Ramalingam S, **Kotsakis A**, Heron D, Tarhini A, Burton S, Smith R, Gooding W, Friedland D, Petro D, Flaugh R, Raez L, Brahmer J, *Greenberger* J, Landreneau R, Luketich J, Belani C, Argiris A: A phase II study of cetuximab in combination with chest radiotherapy and consolidation carboplatin and paclitaxel in patients with stage III non-small cell lung cancer (NSCLC): a preliminary report  
*13<sup>th</sup> World Conference on Lung Cancer (WCLC), 2009 San Francisco, USA*
71. **A. Kotsakis**, A. Tarhini, D. Petro, R. Flaugh, G. Vallabhaneni, C. P. Belani, D. Friedland, A. Argiris. Phase II study of RAD001 (*everolimus*) in previously treated small cell lung cancer (SCLC), (e- abstract)  
*13<sup>th</sup> World Conference on Lung Cancer (WCLC), 2009 San Francisco, USA*
72. Vamvakas L, Agelaki S, Kentepozidis N, Karampeazis A, Pallis A., Christophyllakis Ch, **Kotsakis A**, Boukovinas J, Pavlakou G, Agelidou M, Mavroudis D, Georgoulas V. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): A randomized phase III study  
*46<sup>th</sup> ASCO, June 4-8, 2010, Chicago, USA*
73. S. Agelaki, ED Kontopodis, N. Androulakis, **A. Kotsakis**, V. Georgoulas. A Phase II Trial of Low-dose Metronomic Oral Vinorelbine as Salvage Treatment in Advanced Non-Small Cell

Lung Cancer (NSCLC)

*20<sup>th</sup> International Congress on Anti-cancer Treatment*, 1-5 February 2010, Paris, France

74. **A. Kotsakis**, S. Agelaki, N. Vardakis, L. Vamvakas, A. Kalykaki, N. Kentepozidis, E. Kontopodis, G. Sfakiotaki, D. Mavroudis, V. Georgoulas. Phase I study of the combination of docetaxel (D) and pemetrexed (P) in patients with advanced unresectable or metastatic non small cell lung cancer (NSCLC)  
*20<sup>th</sup> International Congress on Anti-cancer Treatment*, 1-5 February 2010, Paris, France
75. **Kotsakis A.**, Vetsika E.K., Agouraki D., Christou S., Hatzidaki D., Mavroudis D., Georgoulas V: Clinical and immunologic response of patients with advanced Non-Small Cell Lung Cancer (NSCLC) vaccinated with an optimized cryptic hTERT peptide (Vx-001).  
*Advances and Perspectives in Thoracic and upper Aerodigestive Malignancies 10-13 March 2011, Athens, Greece.*
76. G. Milaki, S. Apostolaki, M. Perraki, E. Kontopodis, **A. Kotsakis**, D. Mavroudis, V. Georgoulas. Detection of Cytokeratin-19 mRNA-positive circulating tumor cells (CTCs) in patients with metastatic non-small cell lung cancer (NSCLC)  
*Advances and Perspectives in Thoracic and upper Aerodigestive Malignancies 10-13 March 2011, Athens, Greece.*
77. L. Vamvakas, S. Agelaki, N. Kentepozidis, A. Karampeazis, A.G. Pallis, Ch. Christophyllakis, **A. Kotsakis**, P. Papakotoulas, E. Pavlaku, M. Agelidou, D. Mavroudis, V. Georgoulas. Pemetrexed compared with erlotinib in pre-treated patients with advanced non-small-cell lung cancer (NSCLC): A subgroup analysis for patients over 65 years of age, including geriatric assessment correlation, of a randomized phase III Hellenic Oncology Research Group (HORG) trial  
*Advances and Perspectives in Thoracic and upper Aerodigestive Malignancies 10-13 March 2011, Athens, Greece.*
78. L. Vamvakas, A. Prinari, A. Karampeazis, **A. Kotsakis**, S. Giassas, N. Xenidis, A. Polyzos, A. Athanasopoulos, V. Georgoulas, J. Souglakos. Capecitabine and Oxaliplatin (CAPOX) in combination with Bevacizumab as first line treatment for elderly patients with metastatic colorectal cancer (MCRC): preliminary results of a multicenter phase II trial with complete geriatric assessment from Hellenic Oncology Research Group (HORG)  
*21<sup>th</sup> International Congress on Anti-cancer Treatment*, 1-4 February 2011, Paris, France

79. **Kotsakis A**, Kontopodis E, Vardakis N, Kalbakis K, Kentepozidis N, Xyrafas A, Christofilakis Ch, Mavroudis D, Georgoulas V. A multicentre, randomized phase II study of sequential vinorelbine (V)/cisplatin (C)/ bevacizumab (B) followed by docetaxel (D)/ gemcitabine (G)/ bevacizumab (B) versus docetaxel (D)/cisplatin (C) /bevacizumab (B) as a first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).  
*48<sup>th</sup> ASCO, June 1-5, 2012, Chicago, USA*
80. Varadarajan, P; **Kotsakis, AP**; Martin, D ; Gutkind, JS; Gibson, MK; Argiris, A. Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)  
*48<sup>th</sup> ASCO, June 1-5, 2012, Chicago, USA*
- 81 N. Kentepozidis, Agelidou M., Christophylakis Ch., **Kotsakis A.**, Vardakis N., Stolidis D., Kontopodis E., Xyrafas A., Agelaki S., V. Georgoulas V. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG).  
*ESMO, 28 Sep- 2 Oct, 2012 Vienna, Austria*
82. **Kotsakis A**, Kontopodis E, Vardakis N, Kalbakis K, Kentepozidis N, Xyrafas A, Christofilakis Ch, Mavroudis D, Georgoulas V. A multicenter, randomized phase II study of V (vinorelbine)/C (cisplatin)/B (bevacizumab) followed by D (docetaxel)/G (gemcitabine)/B versus D/ C /B as a first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)  
*ESMO, 28 Sep- 2 Oct, 2012 Vienna, Austria*
83. E. K Vetsika, E. Skalidaki, A. Koutoulaki,, D. Mavroudis, V Georgoulas, **A. Kotsakis**. Assessment of the predictive/prognostic value of the myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs) in Non-small Cell Lung Cancer (NSCLC). Preliminary results  
*ESMO, 28 Sep- 2 Oct, 2012 Vienna, Austria*
84. A.G. Pallis, L. Vamvakas, A. Karampeazis, A. Polyzos, S. Agelaki, N. Kentepozidis, I. Boukovinas, **A. Kotsakis**, E. Papadimitraki, F. Koinis, V. Georgoulas. A phase II study of the combination of bevacizumab with cytotoxic chemotherapy, as first line treatment, in older patients with advanced/metastatic NSCLC (non-squamous).  
*SIOG 2012, Manchester, UK*

85. Demetris Stoltidis, Ippokratis Messaritakis, **Thanos Kotsakis**, Sofia Agelaki, Chara Papadaki, Maria Sfakianaki, Stella Apostolaki, Christos Fokoloros, Demitris Mavroudis, Vassilis Georgoulas, John Souglakos. Detection of Circulating Tumor Cells (CTCs) in the peripheral blood of patients with refractory or resistant Small Cell Lung Cancer (SCLC) treated with Pazopanib as surrogate marker for treatment outcome  
*Advances in Circulating Tumor Cells, 26-29 September, 2012 Athens, Greece*
86. N. Kentepozidis, Agelidou M., Christophylakis Ch., **Kotsakis A.**, Vardakis N., Stoltidis D., Kontopodis E., Xyrafas A., Agelaki S., V. Georgoulas V. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG)  
*24<sup>th</sup> International Congress on Anti-cancer Treatment, 5-12 February 2013, Paris, France*
87. A. Koutoulaki, Z. Zafeiriou, D. Skalidaki, D. Aggouraki, K.E. Vetsika, D. Mavroudis, V. Georgoulas, **A. Kotsakis**. Peripheral Immunosuppressive Cell Levels as Predictive Marker for the Clinical Outcome in Stage IV Colorectal Carcinoma  
*49<sup>th</sup> ASCO, May 31-4, 2013, Chicago, USA*
88. Vetsika E.-K., Koinis P., Aggouraki D., Koutoulaki A., Mavroudis D., Georgoulas V., **Kotsakis A.** Increased levels of Myeloid-Derived Suppressor Cells are associated with clinical outcome in Non-Small Cells Lung Cancer (NSCLC) patients.  
*2<sup>nd</sup> International Symposium on Thoracic and Upper Aerodigestive Malignacies, 4-6 April 2013, Athens, Greece*
89. **A. Kotsakis**, N. Vardakis, S. Agelaki, E. Kontopodis, D. Stoltidis, C. Nikolaou, K. Kalbakis, L.Vamvakas, V.Georgoulas. A randomized phase 2 study of irinotecan/cisplatin (IC) compared to pemetrexed/cisplatin (PC) as second line treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) relapsed after first line treatment with docetaxel/gemcitabine (DG).  
*2<sup>nd</sup> International Symposium on Thoracic and Upper Aerodigestive Malignacies, 4-6 April 2013, Athens, Greece*
90. A.Karampeazis, L.Vamvakas, A.G.Pallis, A.Polyzos, S.Agelaki, N.Kentepozidis, I.Boukovinas, **A.Kotsakis**, E.Papadimitraki, F.Koinis, V.Georgoulas. Docetaxel plus bevacizumab as first-line treatment in older patients with non-squamous, advanced and metastatic non-small-cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group  
*2<sup>nd</sup> International Symposium on Thoracic and Upper*



91. Kentepozidis N, **Kotsakis A**, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulas V. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG).  
*2nd International Symposium on Thoracic and Upper Aerodigestive Malignancies, 4-6 April 2013, Athens, Greece*
92. **A. Kotsakis**, N. Kentepozidis, S. Agelaki, E. Kontopodis, P. Koinis, L. Vamvakas, V. Georgoulas. A pilot phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment: preliminary results.  
*ESMO, European Cancer Conference 2013 (17th ECCO – 38th ESMO – 32nd ESTRO) 27 September - 1 October 2013 Amsterdam, Netherlands,*
93. A. Koutoulaki, Z. Zafeiriou, D. Skalidaki, D. Aggouraki, K.E. Vetsika, D. Mavroudis, V. Georgoulas, **A. Kotsakis**. Peripheral Immunosuppressive Cell Levels as Predictive Marker for the Clinical Outcome in Stage IV Colorectal Carcinoma  
*ESMO, European Cancer Conference 2013 (17th ECCO – 38th ESMO – 32nd ESTRO) 27 September - 1 October 2013 Amsterdam, Netherlands*
94. Ch. Nikolaou, **A. Kotsakis**, S. Apostolaki, M. Spiliotaki, D. Mavroudis, K. Kalbakis, S. Agelaki, V. Georgoulas. Exemestane plus everolimus is effective in decreasing CTC counts in patients with HER2-negative metastatic breast cancer.  
*9th International Symposium on Minimal Residual Cancer, Sep 24-27 2013, Paris, France*
95. **Kotsakis A.**, Kentepozidis N., Karavasilis V., Varthalitis J., Peroukidis S., Ziras N., Res H., Mavroudis D., Georgoulas V., Agelaki S.  
A Phase II Trial of second line Pazopanib in Small Cell Lung Cancer (SCLC) patients: Preliminary results in patients with sensitive disease  
15th World Conference on Lung Cancer. October 27-30, 2013. Sydney, Australia
96. Vetsika E.-K., Koinis F., Aggouraki D., Koutoulaki A., Mavroudis D., Georgoulas V., **Kotsakis A**. High levels of circulating immunosuppressive cells predict worst clinical outcome in Non-Small Lung Cancer (NSCLC) patients  
15th World Conference on Lung Cancer. October 27-30, 2013.

Sydney, Australia

97. L. Vamvakas, A. Karampeazis, S. Agelaki, N. Kentepozidis, A. Polyzos, **A. Kotsakis**, K. Kalbakis, C. Christofyllakis, E. Kontopodis, A.G. Pallis, V. Georgoulis. Carboplatin plus Gemcitabine as first-line treatment in elderly patients with Non-Small-Cell Lung Cancer: preliminary results of a multicenter phase II trial by the Hellenic Oncology Research Group (HORG).  
International Society of Geriatric Oncology, October 24-26. Copenhagen, Denmark
98. Kentepozidis N, **Kotsakis A**, Nikolaou Ch, Nintos G, Soultati A, Agelaki S, Christophyllakis Ch, Agelidou M, Vamvakas L, Georgoulis V. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG)  
*25<sup>th</sup> International Congress on Anti-cancer Treatment, 4-6 February 2014, Paris, France*
99. D. Aggouraki, M. Papadaki, E.K. Vetsika, A. Koutoulaki, **A. Kotsakis**, G. Kallergi, S. Aggelaki, D. Mavroudis, V.Georgoulis. Correlation of Circulating Tumor Cells (CTCs) expressing stemness and EMT phenotypes with immunosuppressive cells in metastatic breast cancer patients.  
AACR, April 5-9, 2014, San Diego, CA
100. Eleni-Kyriaki Vetsika, Filippos Koinis, Marianthi Gioulmpasani, Despoina Aggouraki, Anna Koutoulaki, Eirini Skalidaki, Dimitris Mavroudis, Vassilis Georgoulis, **Athanasios Kotsakis**. High frequency of a circulating monocytic subpopulation of myeloid-derived suppressor cells predicts worst clinical outcome in untreated non-small lung cancer patients.  
AACR, April 5-9, 2014, San Diego, CA
101. S. Agelaki, A. **Kotsakis**, E. Kontopodis, N. Kentepozidis, K. Syrigos, N. Ziras, G. Filippa, L. Vamvakas, D. Mavroudis, V. Georgoulis. Bortezomib in Combination with Gemcitabine (GEM) and Cisplatin (CDDP) in Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Hellenic Oncology Research Group Multicenter Phase II study.  
ASCO May 30 - Jun 3, 2014 Chicago, Illinois.
102. S. Agelaki, M. Spiliotaki, Ch. Nikolaou, E. Politaki, S. Apostolaki, **A. Kotsakis**, D. Mavroudis, V. Georgoulis. Exemestane plus everolimus decreases CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.

ASCO May 30 - Jun 3, 2014 Chicago, Illinois.

103. **A. Kotsakis**, N.Kentepozidis, I.I. Varthalitis, V. Karavassilis, Ep. Samantas, Ch. Christophyllakis, E.K. Dermitzaki, N. Ziras, S. Agelaki, H.P. Kalofonos, D. Mavroudis, V. Georgoulis. A phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment.  
ASCO May 30 - Jun 3, 2014 Chicago, Illinois.
104. N. Kentepozidis, E. Kontopodis, **A. Kotsakis**, Ch. Christophyllakis, E. Saloustros, A. Kalykaki, V. Bozionelou, D. Mavroudis, V. Georgoulis. Docetaxel (D), gemcitabine (G) and bevacizumab (Bev) as salvage chemotherapy (CT) for HER-2 negative metastatic breast cancer (mBC).  
Hellenic- Turkish Congress on Senology, Athens, 19-21 June, 2014.
105. A Karampeazis, N Kentepozidis, **A Kotsakis**, A Ardavanis, V Bozionelou, P Papakotoulas, E Saloustros, D Mavroudis, V Georgoulis, L Vamvakas. Cyclophosphamide and Pegylated doxorubicin (myocet®) in elderly women with HER-2 negative locally advanced or metastatic breast cancer: preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group.  
Hellenic- Turkish Congress on Senology, Athens, 19-21 June, 2014.
106. E. Saloustros, N. Kentepozidis, **A. Kotsakis**, Dermitzaki E.K., A. Polyzos, F. Koinis, Ch. Christophyllakis, K. Kalbakis, S. Agelaki, D. Mavroudis, V. Georgoulis. A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.  
Hellenic- Turkish Congress on Senology, Athens, 19-21 June, 2014.
107. Mountzios Giannis, Emmanouilidis Christos, Vardakis Nikolaos, Kontopodis Emmanouil, Hatzidaki Dora, Popis Evangelos, Karachaliou Niki, **Kotsakis Athanassios**, Agelidou Maria, Georgoulis Vassilis. Paclitaxel plus Bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group.  
The European Lung Cancer Conference (ELCC), Geneva, Switzerland - 26 Mar - 29 Mar 2014
108. **Athanasios Kotsakis**, Nikolaos Kentepozidis, Vassilis Karavassilis, John I Varthalitis, Stavros Peroukidis, Nikolaos Ziras, Helen Res, Dimitrios Mavroudis, Vassilis Georgoulis, Sofia Agelaki. A Phase II Trial of second line Pazopanib in Small

Cell Lung Cancer (SCLC) patients: Preliminary results in patients with sensitive disease.

19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, 9-11 October, 2014, Metropolitan Hotel, Athens, Greece

109. Nikolaos Kentepozidis, **Athanasios Kotsakis**, Christos Nikolaou, George Nintos, Aspasia Soultati, Sofia Agelaki, Charalambos Christophyllakis, Maria Agelidou, Lampos Vamvakas, Vassilis Georgoulis. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG).  
19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, 9-11 October, 2014, Metropolitan Hotel, Athens, Greece
110. Anna Koutoulaki, Nikolaos Kentepozidis, Zafeiris Zafeiriou, Despoina Aggouraki, Kyriaki E Vetsika, Dimitrios Mavroudis, Vassilis Georgoulis, **Athanasios Kotsakis**. Peripheral Immunosuppressive Cell Levels as Predictive Marker for the Clinical Outcome in Stage IV Colorectal Carcinoma.  
19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, 9-11 October, 2014, Metropolitan Hotel, Athens, Greece
111. A Karampeazis, L Vamvakas, N Kentepozidis, S Agelaki, **A Kotsakis**, A Polyzos, G Milaki, Ch Christophyllakis, Ch Kouroussis, D Mavroudis, V Georgoulis. Gemcitabine combined with Carboplatin in the first-line treatment of elderly patients with non-small-cell lung cancer: a multicenter phase II trial by the Hellenic Oncology Research Group (HORG).

<b>Publications in Greek Journals</b>	4
<b>Abstracts in Greek Conferences</b>	43
<b>Speeches in Round Tables-Scientific Meetings</b>	27
<b>Participation in Seminars</b>	10